Retrospective use of PBPK modelling to understand a clinical drug–drug interaction between dextromethorphan and GSK1034702

References

• Atkinson A, Kenny JR, Grime K. (2005). Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry Analysis. Drug Met Disp 33:1637–47
   PubMed Web of Science ®Google Scholar
• Bentley GD, O’neill BV, Robertson J, et al. (2013). The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacology 16:721–31
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Met Disp 31:289–93
   PubMed Web of Science ®Google Scholar
• Callegari E, Kalgutkar AS, Leung L, et al. (2013). Drug metabolites as cytochrome P450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development. Drug Metab Dispos 41:2047–55
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Desta Z, Kerbusch T, Soukhova N, et al. (1998). Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 285:428–37
   PubMed Web of Science ®Google Scholar
• FDA. (2012). Aricept label information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s036,021720s009,022568s006lbl.pdf
   Google Scholar
• Greenblatt DJ, von Moltke LL, Perloff ES, et al. (2006). Interaction of flurbiprofen with cranberry juice, grape juice, tea and fluconazole: in vitro and clinical studies. Clin Pharm Ther 79:125–33
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. (1993). CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197–204
   PubMedGoogle Scholar
• Kanaan Y, Daali P, Dayer J, Desmeules M. (2006). Lack of dextromethorphan interaction with p-glycoprotein. Clin Pharm Ther February 10:PI-7
   Google Scholar
• Lim H-K, Duczak N, Brougham L, et al. (2005). Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6 and CYP1A2 in pooled human liver microsomes. Drug Met Disp 33:1211–19
   PubMed Web of Science ®Google Scholar
• Lund J, Dear G, Lowy MT, Graham J. (2013). A placebo-controlled, single-blind, randomised study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and drug interaction of GSK1034702 (M1 receptor agonist) after repeat doses in healthy subjects for up to 28 days. Biol Psychiatry 73:266S
   Web of Science ®Google Scholar
• Michalets EM. (1998). Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 18:84–112
   PubMed Web of Science ®Google Scholar
• Mori K, Hashimoto H, Takatsu H, et al. (2009). Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica 39:415–22
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336–48
   PubMed Web of Science ®Google Scholar
• Pasternyk Di Marco M, Edwards DJ, Wainer IW, Ducharme MP. (2002). The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 71:1149–60
   PubMed Web of Science ®Google Scholar
• Rosholm JU, Hallas J, Gram LF. (1994). Concurrent use of more than one psychotropic drug (polypsychopharmacy) in outpatients – a prescription database study. Br J Clin Pharmacol 37:533–8
   PubMed Web of Science ®Google Scholar
• Sandson NB, Armstrong SC, Cozza KL. (2005). An overview of psychotropic drug-drug interactions. Psychosomatics 46:464–94
   PubMed Web of Science ®Google Scholar
• Scarr E. (2013). Muscarinic M1 receptor agonists: can they improve cognitive performance? Int J Neuropsychopharmacol 16:717–20
   PubMed Web of Science ®Google Scholar
• Shardlow CE, Generaux GT, MacLauchlin CC, et al. (2011). Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Met Disp 39:2076–84
   PubMed Web of Science ®Google Scholar
• Solon EG. (2012). Use of radioactive compounds and autoradiography to determine drug tissue distribution. Chem Res Toxicol 25:543–55
   PubMed Web of Science ®Google Scholar
• Sproule BA, Naranjo CA, Bremmer KE, Hassan PC. (1997). Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 33:454–71
   PubMed Web of Science ®Google Scholar
• Taylor D, Ladder M. (1996). Cytochromes and psychotropic drug interactions. Br J Psychiatry 168:529–32
   PubMed Web of Science ®Google Scholar
• Uhr M, Namendorf C, Grauer MT, et al. (2004). P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. J Psychopharmacology 18:509–15
   PubMed Web of Science ®Google Scholar
• VandenBrink BM, Foti RS, Rock DA, et al. (2012). Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. Drug Metab Dispos 40:47–53
   PubMed Web of Science ®Google Scholar
• Varsaldi F, Miglio G, Scordo MG, et al. (2006). Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol 62:721–6
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Heydari A, et al. (2006). Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacology 20:842–9
   PubMed Web of Science ®Google Scholar
• Yang J, Liao M, Shou M, et al. (2008). Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Current Drug Met 9:384–94
   PubMed Web of Science ®Google Scholar
• Yeung CK, Fujioka Y, Hachad H, et al. (2011). Are circulating metabolites important in drug-drug interactions?: quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105–13
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome p450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Met Disp 30:1311–19
   PubMed Web of Science ®Google Scholar
• Zanger UM, Fischer J, Raimundo S, et al. (2001). Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573–85
   PubMedGoogle Scholar